Neovasc Inc. EV/EBIT

EV/EBIT of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBIT growth rates and interactive chart. EV/EBIT is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes (EBIT), but after Depreciation and Amortization.. The EV/EBIT ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBIT compared to a stock’s historical average or industry can indicate undervaluation. EV/EBIT takes into account the reinvestment needs of a business (depreciation, amortization).


Highlights and Quick Summary

Current EV/EBIT of Neovasc Inc. is 0.34 (as of December 31, 2021)
  • EV/EBIT for the quarter ending March 31, 2022 was 0.1 (a -71.75% decrease compared to previous quarter)
  • Year-over-year quarterly EV/EBIT increased by Infinity%
  • Annual EV/EBIT for 2021 was 0.34 (a Infinity% increase from previous year)
  • Annual EV/EBIT for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBIT for 2019 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBIT of Neovasc Inc.

Most recent EV/EBITof NVCN including historical data for past 10 years.

Interactive Chart of EV/EBIT of Neovasc Inc.

Neovasc Inc. EV/EBIT for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.1
2021 0.34 0.0 0.0 0.2 0.34
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 0.0 0.0 0.0 0.0 0.0
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.